Artificial Intelligence
Predictive Oncology (NASDAQ Symbol POAI) is licensing and partnering this groundbreaking NSP10 technology in the race to develop a vaccine for development
MINNEAPOLIS, May 14, 2020 (GLOBE NEWSWIRE) — Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter, entered the race to develop a COVID19 vaccine. The ground-breaking vaccine technology is based on a self-assembling nanoparticle called NSP10 which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin (1).
NSP10 Vaccine Technology: How Does it work and Why is it a “Game Changer”?NSP10 Nanoparticle has special surface properties that allow for the rapid design and display of viral receptor stems for virtually any virus, making it extremely versatile. “Couple these properties with the extraordinary immunogenic properties and you have a potentially “game changing” technology,” according to Dr. Joel Dobbs, a retired pharmaceutical industry executive, who is now Executive-in-Residence at UAB’s Collat School of Business, “this is a truly transitional technology that could change the way vaccines are made in the future.”Previous vaccine studies of NSP10-based Nanoparticles in rabbits produced exceptionally high titers against a herpes viral protein called glycoprotein D, normally non-highly antigenic (Titer refers to the number of times the blood serum can be diluted and still react with the virus antigen). Titers in this case ranged from 1:1,000 with a simple injection of 500 micrograms of plasmid DNA, to as much as 1:25,000 after a second booster (third injection) – all without the use of adjuvants or transfection agents (2). To our knowledge, this is unprecedented and revolutionary for a DNA vaccine. The exact reasons why the NSP10-based Nanoparticles exhibit these properties is still a subject of study, but scientists know that nanoparticles are processed differently by the immune system (3) and smaller nanoparticles can often produce higher titers – NSP is one of the smallest currently evaluated.The level of titer is important for many reasons, for example, earlier animal experiments with vaccines focused on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) found that low antibody levels could potentially lead to dysfunctional immune responses, increasing infection and damaging the lungs (4). In addition to enhanced protective immunity, stronger titers mean that it takes less vaccine per dose which has added advantages in safety and production scale. In the special case of NSP10-based vaccines, as it translates to humans, this could mean that a single gram of plasmid DNA can potentially immunize as many as 2,000 people, perhaps more. According to Dr. Daniel Carter, the inventor of this technology (5), “this suggests that if we see similar titers in humans, no atypical resources or capabilities are required to manufacture the vaccine at a sufficient scale to impact the pandemic.” For example, a single bacterial fermentation at commercial scale can in a span of 2 to 3 days, produce enough raw material to eventually immunize millions of people – “merge this with the well-established processes for purifying injectable-grade plasmid DNA (which can also be done in short order) and you have the potential for a disruptive game changing technology,” said Dr. Carter.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99c5c11c-8099-44a7-af8d-8531cc437011D. C. Carter and C. Li, “Genetically Engineered Ferritin as a Vehicle for Vaccine Production, Biomaterials, Oxygen Transport, and Therapeutic Delivery, issued in Germany, France, United Kingdom, China and Canada, US Patent No. 7,097,841(2006).D.C. Carter, B. Wright, W. Gray Jerome, J. Rose and E. Wilson, “ A Unique Protein Self-Assembling Nanoparticle with Significant Advantages in Vaccine Development and Production, J. of Nanomaterials, Vol 2020, Article ID: 4297937 (2020).Tokatlian T, Read BJ, Jones CA, Kulp DW, Menis S, Chang JYH, et al. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science. 363(6427):649-54 (2019).J. Cohen, “COVID19 Shot Protects Monkeys,” Science, 368(6490), 456-467 (2020).D. C. Carter, “NSP10 Self-Assembling Fusion Proteins for Vaccines, Therapeutics, Diagnostics and other Nanomaterial Applications,” US Patent Appln: US2018/0326044 Issuing (2020), Canada Pending.About Dr. CarterDr. Carter has over 30 years of experience in the leadership and management of science in both the government and private sectors with core science expertise in molecular structural biology, protein engineering, protein production and microgravity science and applications. He has maintained an internationally recognized research program throughout his career, authoring over 60 peer reviewed papers which include publications in Science, Nature and PNAS and is the inventor on more than 24 patents. His publications are highly cited (~13,500) with a current h-index ranking of 40.Dr. Carter’s research focus areas include: (1) understanding the atomic structure and chemistry of albumin, the principal protein of the circulatory system and key pharmacokinetic effector of virtually all pharmaceuticals; (2) development and applications of self-assembling nanomaterial platforms for vaccine, therapeutic and diagnostic applications; and (3) microgravity science and applications.Prior to his career in the commercial biotechnology sector, Dr. Carter was employed by NASA for a period of 11 years in progressively more responsible positions including Chief of the Biophysics and Advanced Materials Branch, as well as, the prestigious SST appointment as the NASA Senior Scientist for Biophysics. While at NASA and New Century Pharmaceuticals, Inc., Dr. Carter also served as the Principal Investigator on an extensive series of multi-user microgravity protein crystal growth experiment payloads carried out on board the Space Shuttle, Mir and International Space Station, which included a large international co-investigator group of scientists from academics and industry. During his tenure at NASA, Dr. Carter was the recipient of many awards including NASA Inventor of the Year Awards and the NASA Exceptional Service Medal.About Predictive Oncology Inc.Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi- omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.Forward-Looking StatementsCertain of the matters discussed in this press release contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include: we may not be able to continue operating without additional financing; current negative operating cash flows; the terms of any further financing, which may be highly dilutive and may include onerous terms; no assurance that a vaccine will be successfully developed in collaboration with Dr. Daniel Carter, or that definitive documentation of all arrangements with Dr. Carter will be completed, risks related to the 2019 merger with Helomics including; 1) significant goodwill could result in further impairment; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources; risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; risks related to the transaction with Quantitative Medicine including: 1) completion of the transaction; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources; risk that we will be unable to complete the transaction with InventaBioTech to acquire Soluble Therapeutics and BioDtech; risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property; the impact of competition; acquisition and maintenance of any necessary regulatory clearances applicable to applications of our technology; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; risk that we never become profitable if our product is not accepted by potential customers; possible impact of government regulation and scrutiny; unexpected costs and operating deficits, and lower than expected sales and revenues, if any; adverse results of any legal proceedings; the volatility of our operating results and financial condition; and, and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov.Investor Relations Contact:Hayden IR
James Carbonara
(646)-755-7412
[email protected]
Artificial Intelligence
LambdaTest launches LambdaTest extension for GitHub Copilot to make test automation pervasive across SDLC and drive developer productivity
NOIDA, India and SAN FRANCISCO, May 22, 2024 /PRNewswire/ — LambdaTest extension for GitHub Copilot enables AI-powered bridge experiences by seamlessly integrating test and dev workflow. It acts as a test automation copilot, assisting developers with quality assurance capabilities across different stages in SDLC, right where they code.
May 22, 2024, Noida/San Francisco: LambdaTest, a leading cloud-based unified testing platform, announced the launch of the LambdaTest extension for GitHub Copilot. This innovative capability revolutionizes the way developers manage and execute test workflows within their integrated development environments (IDEs).
The LambdaTest extension seamlessly integrates with GitHub Copilot Chat bridging the gap between development and testing workflows. Developers can now trigger test execution directly from their GitHub and VS Code environment, eliminating the need to switch between multiple applications. This streamlined process enhances productivity and accelerates software delivery.
With LambdaTest extension, developers can initiate tests effortlessly with a simple command, bringing testing closer to their code. This capability not only saves time but also enhances collaboration among development and testing teams by providing a unified platform for managing quality software releases, faster.
Moreover, real-time feedback integrated into GitHub Copilot empowers developers to iterate more efficiently, at speed, ensuring the quality and stability of their codebase. By conveniently viewing regression run results within their coding environment, developers and testers can quickly identify and address potential issues or bugs, facilitating faster resolution and delivery of high-quality software.
“LambdaTest Extension for GitHub Copilot is a huge milestone in our commitment to enable devs and QA processionals worldwide with frictionless experiences to accelerate software delivery.,” said Mohit Juneja, VP, Strategic Sales and Partnerships, LambdaTest. “Gone are the days of switching between multiple applications; now, developers can design, trigger, and analyze tests with simple prompts in natural language, without switching context from the IDE.”
The benefits of the LambdaTest extension extend beyond just test execution. It also offers powerful analysis tools, allowing developers to dive deep into test data, identify trends, and make data-driven decisions to continuously improve code quality and stability.
LambdaTest remains committed to driving innovation in the field of software testing, and this capability is another testament to that commitment. By providing developers and testers with tools to streamline processes and deliver high-quality software efficiently, LambdaTest continues to support and empower software development teams worldwide.
The LambdaTest extension for GitHub Copilot is now available for developers and testers. To learn more and get started, visit https://github.blog/2024-05-21-introducing-github-copilot-extensions
About LambdaTest LambdaTest is an intelligent and omnichannel enterprise execution environment that helps businesses drastically reduce time to market through Just in Time Test Orchestration (JITTO), ensuring quality releases and accelerated digital transformation. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
Browser & App Testing Cloud allows users to run both manual and automated tests of web and mobile apps across 3000+ different browsers, real devices, and operating system environments.HyperExecute helps customers run and orchestrate test grids in the cloud for any framework and programming language at blazing-fast speeds to cut down on quality test time, helping developers build software faster.For more information, please visit, https://lambdatest.com
Logo – https://mma.prnewswire.com/media/1721228/Lambda_Test_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/lambdatest-launches-lambdatest-extension-for-github-copilot-to-make-test-automation-pervasive-across-sdlc-and-drive-developer-productivity-302153117.html
Artificial Intelligence
DeepL announces $300 million investment at $2 billion valuation fueled by global demand for AI language solutions
Index Ventures led heavily oversubscribed round with participation from late-stage investment firms ICONIQ Growth, Teachers’ Venture Growth, and more Rapid enterprise adoption of DeepL has fueled the company’s growth in 60+ global markets for 100,000+ businesses, governments, and other organizationsDeepL’s Language AI Platform for business provides category-leading AI-powered translation and writing solutions COLOGNE, Germany, May 22, 2024 /PRNewswire/ — DeepL, a leading Language AI company, today announced $300 million of investment at a $2 billion valuation. Led by Index Ventures, the heavily oversubscribed round attracted strong support from new investors, who will bring their extensive expertise, connections, and resources to support DeepL’s growth and long-term vision to transform the way companies communicate around the world. Additional late-stage investors, including ICONIQ Growth, Teachers’ Venture Growth, and others, also participated, along with existing investors IVP, Atomico, and WiL.
“We’re approaching an inflection point in the AI boom where businesses who are racing to adopt the technology begin to discern between hype versus solutions that are secure and actually solve real problems in their business,” said Jarek Kutylowski, founder and CEO of DeepL. “This new investment comes during what is on track to be DeepL’s most transformative year yet and is a testament to the crucial role that our Language AI platform has in solving the complex linguistic challenges global companies face today. We’re highly focused on continued growth and innovation to expand our solutions and ensure they remain industry-leading in terms of quality, precision, and security. This will bring us closer to a future where every company, regardless of location, can operate seamlessly on a global scale with our AI.”
The new investment comes during a period of significant growth and momentum for DeepL, which has amassed a customer network of 100,000+ businesses, governments, and other organizations worldwide. This network includes Zendesk, Nikkei, Coursera, and Deutsche Bahn, who rely on its highly accurate and secure enterprise Language AI platform to deliver seamless communication, driving international growth and cost savings. In response to surging demand from global enterprises, DeepL has accelerated its expansion efforts and strategic investments into key markets over the past year. In January 2024, DeepL deepened its commitment to the U.S.—now its third largest market—by opening its first office in the region. The company continues to expand its team in the U.S. to support growing demand.
Within the last 12 months, DeepL has also substantially broadened its product offerings tailored for businesses. In April 2024, the company launched DeepL Write Pro, a writing assistant specifically tailored for business writing, powered by its own proprietary LLM technology. The company also continues to expand the range of languages supported by its platform with the recent additions of Arabic, as well as Korean and Norwegian, bringing its total number of languages to 32.
“DeepL’s runaway success is a bit of an ‘open secret’ in the business community,” said Danny Rimer, who led the investment from Index Ventures. “The company is exceptionally thoughtful about creating cutting-edge AI products that deliver real and immediate value to their customers. Jarek and the rest of the DeepL team are equally research and commercially minded – both of which are key to the company’s success.” Index Ventures is recognized for its investments in highly successful SaaS businesses like Figma, Slack, Wiz, and Scale AI.
Demand for AI solutions among global enterprises is on the rise. A recent IBM study found that 42% are already actively deploying AI and 40% are exploring its potential. Within this rapidly evolving landscape, DeepL is leading the way in applying AI to transform the $67.9 billion language industry, which is projected to grow to $95.3 billion by 2028.
Since its inception in 2017, DeepL has become the Language AI provider of choice for businesses across multiple industries including manufacturing, legal, retail, healthcare, technology, and professional services. The company’s specialized Language AI platform has become a critical investment for global businesses today, addressing a variety of communication challenges ranging from internal communications to customer support and international market expansion. Unlike general-purpose AI systems, DeepL’s cutting-edge translation and writing solutions rely on specialized AI models specifically tuned for language, resulting in more precise translations for a variety of use cases and a reduced risk of hallucinations and misinformation. In business translation and writing, accuracy is paramount, making specialized AI models the most reliable and preferred solution for language challenges.
DeepL’s Language AI platform is also proven to drive significant cost savings and efficiencies. A 2024 Forrester study revealed that the use of DeepL delivered 345% ROI for global companies, reducing translation time by 90% and driving a 50% in workload reduction, underscoring, in our opinion, the power of its platform for businesses looking to grow their revenue and enter new markets faster and at scale.
“At Zendesk we see first hand the power of infusing AI tools into customer experience, and DeepL’s industry-leading translation is a prime example,” said Adrian McDermott, CTO, Zendesk. “The ability to have accurate AI translation allows companies from startups to large enterprises the ability to scale globally, reaching prospects and existing customers in new ways. Zendesk’s open and flexible platform allows for seamless partnerships, and the tangible results we’ve seen so far from joint customers have us looking forward to continued work with DeepL.”
Looking ahead, DeepL will continue to invest in research and product innovation to strengthen its suite of leading AI communication tools for businesses. The company is also doubling down on global market expansion and talent recruitment across multiple areas including AI research, product, engineering, and GTM.
About DeepLDeepL is on a mission to break down language barriers for businesses everywhere. Over 100,000 businesses, governments and other organizations and millions of individuals in 63 global markets trust DeepL’s Language AI platform for human-like translation and better writing. Designed with enterprise security in mind, companies around the world leverage DeepL’s AI solutions that are specifically tuned for language to transform business communications, expand markets and improve productivity. Founded in 2017 by CEO Jaroslaw (Jarek) Kutylowski, DeepL today has over 900 passionate employees and is supported by world-renowned investors including Benchmark, IVP and Index Ventures.
Contact:Sebastian RiesOpeners [email protected]+49 1578 058 8488
Logo – https://mma.prnewswire.com/media/2419636/DeepL_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/deepl-announces-300-million-investment-at-2-billion-valuation-fueled-by-global-demand-for-ai-language-solutions-302153042.html
Artificial Intelligence
Hyundai Motor and Plus Announce Collaboration to Demonstrate First Level 4 Autonomous Fuel Cell Electric Truck in the U.S.
Hyundai Motor and Plus collaboration aims to enhance road safety and freight efficiencies by demonstrating benefits of XCIENT Fuel Cell truck equipped with Plus’s Level 4 autonomous driving softwareHyundai Motor’s Class 8 XCIENT Fuel Cell truck featuring Plus’s Level 4 SuperDrive™ system is on display at the Plus ACT Expo booth (#2044)LAS VEGAS and SEOUL, South Korea, May 22, 2024 /PRNewswire/ — Hyundai Motor Company (Hyundai Motor) and autonomous driving software leader Plus today unveiled the first Level 4 autonomous Class 8 hydrogen fuel cell electric truck in the U.S. at the Advanced Clean Transportation (ACT) Expo, the largest advanced clean transportation technology and fleet event in North America.
A result of the collaboration between Hyundai Motor and Plus, Hyundai Motor’s XCIENT Fuel Cell truck, equipped with Plus SuperDrive™ Level 4 autonomous driving technology, is on display at the Plus ACT Expo booth (#2044).
The Level 4 autonomous XCIENT Fuel Cell truck is undergoing initial autonomous driving assessments in the U.S., making it the first-ever Level 4 self-driving test on a Class 8 fuel cell electric truck to take place in the country. The collaboration seeks to show that autonomous hydrogen fuel cell trucks can help make trucking safer, more efficient, and more sustainable.
“We are excited to showcase our collaboration with Plus to test Level 4 autonomous driving technology with our Class 8 XCIENT Fuel Cell truck,” said Martin Zeilinger, Executive Vice President and Head of Commercial Vehicle Development at Hyundai. “Hyundai Motor has been driving the energy transition paradigm with our advanced fuel cell technologies. By adding autonomous capabilities to our world’s first mass-produced hydrogen-powered XCIENT Fuel Cell truck, Hyundai is looking forward to providing fleets and vehicle operators additional solutions that enhance road safety and freight efficiencies thanks to Plus’s industry-leading autonomous driving technology.”
First introduced in 2020, Hyundai Motor’s XCIENT Fuel Cell truck has conducted commercial operations in eight countries worldwide, establishing a successful track record of real-world applications and technological reliability.
At last year’s ACT Expo, Hyundai introduced XCIENT Fuel Cell tractor, the commercialized Class 8 6×4 fuel cell electric model, powered by two 90kW hydrogen fuel cell systems and a 350kW e-motor, providing a driving range of over 450 miles per charge even when fully loaded.
Plus’s SuperDrive™ solution is being deployed across the U.S., Europe, and Australia. The system uses a combination of cutting-edge sensors, including LiDAR, radar and cameras, to provide surround perception, planning, prediction and self-driving capabilities.
“We are thrilled to collaborate with Hyundai Motor Company on this important initiative to create more sustainable and safe transportation options. A decarbonized future with autonomous hydrogen fuel cell electric trucks that also improve safety and efficiency is one that Plus is proud to support with our cutting-edge autonomous driving technology,” said Shawn Kerrigan, COO and Co-Founder at Plus.
Hyundai Motor and Plus have released a video highlighting their collaboration, which can be seen here: https://www.youtube.com/watch?v=_d19h_v7abo.
About Hyundai Motor Company
More information about Hyundai Motor and its products can be found at: https://www.hyundai.com/worldwide/en/ or Newsroom: Media Hub by Hyundai
About Plus
For more information, visit http://www.plus.ai/.
Photo – https://mma.prnewswire.com/media/2417773/2___Image__Hyundai_Motor_and_Plus_Announce_Collaboration_to_Demonstrate_First_Level_4_Autonomous_Fue.jpg
View original content:https://www.prnewswire.co.uk/news-releases/hyundai-motor-and-plus-announce-collaboration-to-demonstrate-first-level-4-autonomous-fuel-cell-electric-truck-in-the-us-302151236.html
-
Artificial Intelligence6 days agoJapan Data Center Market Investment to Reach $14.48 Billion by 2028 – Watch Out Exclusive Insight on Japan & Hong Kong Data Center Market – Arizton
-
Uncategorized5 days agoCoca-Cola: The future is ‘AI meets human ingenuity’
-
Artificial Intelligence6 days agoStrava Unveils New Chapter of Accelerated Product Development at Brand’s Flagship Event
-
Artificial Intelligence5 days agoMore than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
-
Artificial Intelligence6 days agoData Center Colocation Market Worth USD 58.4 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.
-
Uncategorized5 days ago
The rise of intelligent automation as a strategic differentiator
-
Uncategorized6 days ago
SoftBank looks at ‘softening’ angry customer calls with AI
-
Artificial Intelligence6 days ago
IoT Sensors Market to be Worth $71.6 Billion by 2031- Exclusive Report by Meticulous Research®
